On Friday, Tandem Diabetes Care received a positive adjustment to its Relative Strength (RS) Rating, from 78 to 84.
IBD's unique RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks matches up against the rest of the market.
Decades of market research shows that the stocks that go on to make the biggest gains often have an 80 or higher RS Rating in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
While Tandem Diabetes Care is not near an ideal buy point right now, see if it manages to form and break out of a proper consolidation.
Tandem Diabetes Care showed 0% EPS growth in its most recent report, while sales growth came in at 13%. Look for the next report on or around Nov. 6.
Tandem Diabetes Care earns the No. 65 rank among its peers in the Medical-Products industry group. LeMaitre Vascular, Insulet and Bioventus are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
